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Abstract
Background: Human umbilical cord blood-derived unrestricted somatic stem cells (USSCs),
which are capable of multilineage differentiation, are currently under investigation for a number of
therapeutic applications. A major obstacle to their clinical use is the fact that in vitro expansion is
still dependent upon fetal calf serum, which could be a source of pathogens. In this study, we
investigate the capacity of three different stem cell culture media to support USSCs in serum-free
conditions; HEScGRO™, PSM and USSC growth mediumACF. Our findings demonstrate that
USSCs do not grow in HEScGRO™ or PSM, but we were able to isolate, proliferate and maintain
multipotency of three USSC lines in USSC growth mediumACF.
Results: For the first one to three passages, cells grown in USSC growth mediumACF proliferate
and maintain their morphology, but with continued passaging the cells form spherical cell
aggregates. Upon dissociation of spheres, cells continue to grow in suspension and form new
spheres. Dissociated cells can also revert to monolayer growth when cultured on extracellular
matrix support (fibronectin or gelatin), or in medium containing fetal calf serum. Analysis of
markers associated with pluripotency (Oct4 and Sox2) and differentiation (FoxA2, Brachyury,
Goosecoid, Nestin, Pax6, Gata6 and Cytokeratin 8) confirms that cells in the spheres maintain their
gene expression profile. The cells in the spheres also retain the ability to differentiate in vitro to
form cells representative of the three germline layers after five passages.
Conclusions:  These data suggest that USSC growth mediumACF  maintains USSCs in an
undifferentiated state and supports growth in suspension. This is the first demonstration that
USSCs can grow in a serum- and animal component-free medium and that USSCs can form spheres.
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Background
Human umbilical cord blood contains a subset of stem
cells that can differentiate into cells representative of all
three germline layers [1-4]. We follow Kögler, the first to
describe the multilineage capacity of these cells in vivo, in
calling them "unrestricted somatic stem cells" (USSCs)
[1]. A number of studies demonstrate the therapeutic
potential of USSCs in bone healing, as accessory cells to
reduce graft-versus-host disease, in the repair of myocar-
dial infarcts and as vehicles for gene therapy [1,3,5-8].
Although USSCs are rare compared to haematopoietic
stem cells in cord blood, they can be expanded rapidly to
yield large numbers of cells for study or transplantation.
Culturing of USSCs depends on growth in medium con-
taining a high concentration of specific batches of fetal
calf serum. When cultured in fetal calf serum, USSCs form
an adherent monolayer, do not require a feeder layer, and
can be cultured without differentiating or losing their pro-
liferative capacity.
Before USSCs can be used therapeutically, a method for
large scale amplification of cells under Good Manufactur-
ing Practice (GMP) conditions is necessary, preferably
using defined medium free of xenobiotic components.
Fetal calf serum contains undefined factors, which may
vary from batch to batch, and that may activate or inhibit
stem cell differentiation. The growth of cells in defined
medium not only reduces variability, but also eliminates
the need for costly and time consuming fetal calf serum
batch testing. Additionally, medium that is free of non-
human products reduces concerns about transmission of
infectious cross-species pathogens (such as prions or zoo-
nosis), and possible immunogenic responses to non-
human proteins [9-11].
Here we investigate the capacity of three different stem cell
culture media HEScGRO™, PSM and USSC growth medi-
umACF to enable maintenance of USSCs in serum-free con-
ditions.
PSM is of interest as it contains Sphingosine-1-phosphate
(S1P) and platelet-derived growth factor (PDGF), factors
known to enable the survival and proliferation of human
embryonic stem (hES) cells in an undifferentiated state for
a prolonged period of time [12,13].
S1P is a bioactive sphingolipid present in serum that
binds to its own G protein-coupled receptors, sphingo-
sine-1-phosphate receptor 1 to 5 (S1P(1-5)), and activates
various intracellular signaling pathways depending on the
cell type [14-18]. S1P regulates key biological processes
such as cell proliferation, motility, migration and survival
in both adult and embryonic stem cell types [13,19-21].
PDGF is a growth factor, also present in serum, that is
widely described as a potent mitogen [22]. PDGF is com-
prised of homo- and hetero-dimeric isoforms of polypep-
tide chains A, B, C and D [23,24]. The response of a cell to
a given isoform of PDGF is dependent on the signaling
pathways activated by the two platelet-derived growth fac-
tor receptors (PDGFR-α and PDGFR-β), and the capacity
of the cell to respond to these signals [25-27].
HEScGRO™ is a commercial serum- and animal compo-
nent-free, defined medium known to support the growth
and pluripotency maintenance of hES cells. The media
contains FGF2 (basic FGF) that, like PDGF, has been
reported as having proliferative and differentiation effects
on various cell types [28], and figures quite prominently
in numerous other adult [29], or embryonic-derived stem
cell media formulations [30].
Results
USSCs form spheres in USSC growth mediumACF
We have analyzed the growth of USSCs in three serum-
free media formulations; HEScGRO, PSM and USSC
growth mediumACF. Figures 1A clearly demonstrate that
cells cultured in HEScGRO and PSM do not grow, whereas
cells grown in USSC growth mediumACF proliferate at the
same rate as cells grown in stem cell proliferation medium
containing 30% fetal calf serum.
However, after one to three passages in USSC growth
mediumACF  cells start to form small clusters, which
become tight spheres after a further 24 hours (Figure 1B).
These spheres are initially heterogeneous in shape, but
with continued culturing, rounded spheres with defined
borders are observed. Seven days after their first appear-
ance, the size of the spheres varies. Figure 1C shows that
the majority of spheres (64%) are small in diameter (<120
μm), 31% are medium (120-240 μm) and the remaining
spheres (5%) are large (>240 μm). The smallest sphere
observed was 30 μm, and the largest was 475 μm.
Figure 1D shows that the spheres can be mechanically dis-
sociated and can reform spheres upon culturing in USSC
growth mediumACF. Evidence of proliferation was
observed as spheres could be passaged and new spheres
were observed to form.
As the culturing of stem cells as spheres is important for a
number of applications, we set out to confirm whether
USSCs could form spheres using one of the standard
sphere formation methods [31,32]. Using the serum-free
hanging drop method, we cultured cells either in USSC
growth mediumACF, or stem cell proliferation media with-
out fetal calf serum. Figure 2A shows that cells grown in
stem cell proliferation media without fetal calf serum in
the presence or absence of bFGF do not form spheres, butBMC Biotechnology 2009, 9:101 http://www.biomedcentral.com/1472-6750/9/101
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cells grown in USSC growth mediumACF  always form
spheres. There also appears to be a differential effect on
the morphology of the sphere depending on whether
bFGF is used, in that spheres derived using bFGF are
smaller, but tighter, and have less of a halo.
To determine their structure, spheres were serially sec-
tioned and stained with haematoxylin and eosin. Figure
2B shows representative images of a serial section of a
sphere. The cells in the spheres appear homogenous in
size and morphology and 48% of the spheres also con-
tained cavities.
Altogether, these data suggest that USSC growth mediu-
mACF enables USSC proliferation, that this growth occurs
simultaneously with the loss of the cells' ability to adhere
to plastic, and that these non-adherent cells can continue
to grow in suspension as spheres.
USSC-derived spheres can revert to monolayer growth
The ability of mechanically dissociated spheres to revert to
monolayer growth and continue to proliferate was stud-
ied after culture in USSC growth mediumACF on fibronec-
tin or gelatin coated surfaces, or in the presence of stem
cell proliferation media containing fetal calf serum. Figure
Derivation and maintenance of spheres Figure 1
Derivation and maintenance of spheres. A, Growth kinetics of USSCs cultured in stem cell proliferation medium, HESc-
GRO and PSM and USSC growth mediumACF. Cells were seeded at low density and total cell number was determined every 
two days. B, Time course of the formation of spheres. i, USSCs in stem cell proliferation medium; ii-iv, USSCs in USSC growth 
mediumACF; ii, after three passages USSCs begin to cluster; iii, within 24 hours of formation, clusters detach from the surface; 
iv, with continued culturing, clusters increase in size and have defined boundaries. (Magnification, ×200; scale bar is 100 μm)C, 
Size of spheres on day seven. (Magnification, ×100; scale bar is 100 μm)D, Growth of spheres after mechanical dissociation and 
re-plating on extracellular matrix-coated and non-ECM-coated surfaces; i, clusters of cells continue to grow in USSC growth 
mediumACF; ii, dissociated spheres can grow as an adherent monolayer on fibronectin and collagen-coated surfaces in USSC 
growth mediumACF; iii, dissociated spheres can grown as an adherent monolayer on gelatin-coated surfaces in USSC growth 
mediumACF; iv, in the absence of mechanical dissociation, spheres cultured in stem cell proliferation media grow as an adherent 
monolayer. (Magnification, ×200; scale bar is 100 μm).BMC Biotechnology 2009, 9:101 http://www.biomedcentral.com/1472-6750/9/101
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Characterisation of spheres Figure 2
Characterisation of spheres. A, Morphology of spheres seven days after seeding at high density (1 × 104 cells/30 μl) as 
hanging drops in the presence or absence of bFGF in: i, stem cell proliferation medium without fetal calf serum; or ii, USSC 
growth mediumACF. (Magnification, ×200; scale bar is 100 μm) B, Serial sections of spheres stained with haematoxylin and 
eosin, generated by culturing in USSC growth mediumACF for seven days at both ×200 and ×400 magnification; scale bar is 100 
μm.BMC Biotechnology 2009, 9:101 http://www.biomedcentral.com/1472-6750/9/101
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1D shows that the cells from the spheres re-adhere and
morphologically resemble the parental USSCs in the pres-
ence of fetal calf serum, or when the surface is coated with
extracellular matrix proteins. These cells were cultured for
up to two weeks, during which they were passaged three
times and expanded up to six-fold. This confirms that cells
within the spheres, which have been cultured in USSC
growth mediumACF, can revert to monolayer growth and
continue to proliferate.
USSCs maintain their multipotentiality when cultured as 
spheres
To determine if day seven spheres express pluripotency-
associated markers, the expression of Oct4 and Sox2 was
determined by RT-PCR. Figure 3 shows that USSCs grown
in adherent culture do not express Oct4, but do express
Sox2, and that USSCs grown as spheres maintain this
expression profile. In view of recent reports questioning
accurate detection of Oct4 mRNA expression [33], we con-
firmed that the primers used in this study do not bind to
Oct4B (isoform 2) and are specific to the cDNA of the
nuclear-localized Oct4A (isoform 1). We also confirmed
this result using antibody staining. The antibody staining
clearly detects nuclear-localized Oct4 in hES cells, but
expression could not be detected in USSCs nor seven day
spheres (Figure 4).
To determine if the cells in the spheres initiate a differen-
tiation program, we analysed markers associated with
commitment of stem cells. Figures 3 and 5 show there is
no change in the expression profile of markers associated
with ectodermal (Pax6 and Nestin), mesodermal (Brachy-
ury and Goosecoid) and endodermal (FoxA2, Cytokeratin 8
and  Gata6) differentiation in day seven spheres when
compared to USSCs. This expression profile is also main-
tained after five passages as determined by RT-PCR for
Sox2, Pax6, Gata6, and Brachyury (Figure 6).
Spheres can be differentiated to show expression of 
markers representative of the three germline layers
To confirm that the differentiation capacity of the cells in
the spheres had been maintained; seven day spheres were
dissociated and incubated in lineage-specific differentia-
tion medium. Figure 7 shows that the cells within the
Gene expression profile seven days after sphere formation Figure 3
Gene expression profile seven days after sphere formation. A, RT-PCR for pluripotency-associated genes. RT-PCR 
shows an absence of Oct4 gene expression in both USSCs and seven day spheres, yet demonstrates expression of the another 
pluripotency-associated marker Sox2. Lane 1, hES cells; Lane 2, RT-negative control of the hES cells; Lane 3, USSCs; Lane 4, 
RT-negative control of the USSCs; Lane 5, day seven spheres; Lane 6, RT-negative control of the day seven spheres; and Lane 
7, water control. B, RT-PCR of genes representative of the three germline layers show that day seven spheres maintain the 
same expression profile as adherent USSCs. Lane 1, USSCs; Lane 2, RT-negative of the USSCs; Lane 3, day seven spheres; Lane 
4, RT-negative for the day seven spheres; Lane 5, water control; Lane 6, positive control, spontaneously differentiated hES 
cells; Lane 7, RT-negative of the spontaneously differentiated hES cells. The house keeping gene GAPDH was used as a positive 
control.BMC Biotechnology 2009, 9:101 http://www.biomedcentral.com/1472-6750/9/101
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Oct4 staining on USSC-derived spheres Figure 4
Oct4 staining on USSC-derived spheres. Representative microscopy images of seven day spheres fixed and stained with 
an Oct4 antibody (Alexa488; green) and counter stained with 4, 6-diamidino-2-phenylindole (DAPI; blue). As a positive control, 
the nuclear localisation of the Oct4 antibody was confirmed in hES cells. USSCs were also probed to confirm the Oct4 status 
of the starting cell population. The respective negative isotype control images are also shown. USSCs and seven day spheres do 
not express Oct4 at the protein level. (Magnification, ×200; scale bar is 100 μm).BMC Biotechnology 2009, 9:101 http://www.biomedcentral.com/1472-6750/9/101
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Cytokeratin 8 staining on USSC-derived spheres Figure 5
Cytokeratin 8 staining on USSC-derived spheres. A, As a positive control for CK8 expression, primary human bron-
chial epithelial (16HBE14o-) cells were stained. B, Representative microscopy images of seven day spheres fixed, sectioned and 
stained with a Cytokeratin 8 (CK8) antibody (Alexa488; green) and counter stained with 4, 6-diamidino-2-phenylindole (DAPI; 
blue). The respective negative isotype control images are also shown. (Magnification ×200; scale bar is 100 μm.)BMC Biotechnology 2009, 9:101 http://www.biomedcentral.com/1472-6750/9/101
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spheres maintain the ability to differentiate and express
markers representative of the three germline layers. Cells
expressing neuronal-specific β-tubulin III (a marker of
ectodermal cells), that stain positive for mineralization as
detected by Alizarin Red S staining (a marker of mesoder-
mal cells) and express epithelial-specific surfactant pro-
tein-C (a marker of endodermal cells) were all observed.
The differentiation capacity of the cells is also maintained
after five passages in USSC growth mediumACF (Figures 8
and 9).
Discussion
With the goal of deriving clinically safe USSCs, we aimed
to culture established USSCs in the serum- and animal
component-free medium, USSC growth mediumACF. We
observe that USSCs continue to proliferate in USSC
growth mediumACF, but after one to three passages, the
cells aggregate and grow in suspension as spheres. We
show that spheres can be dissociated and can continue to
grow for five passages, as long as they are dissociated
before the sphere becomes cystic. We also show the
spheres can revert to monolayer growth when provided
with extracellular matrix support or when plated in
medium containing fetal calf serum. Cells passaged in
USCC growth mediumACF maintained their gene expres-
sion profile as judged by Sox2, Brachyury, Pax6 and Gata6
expression. Cells also maintained their capacity to form
bone-like Alizarin red positive cells, SPC positive epithe-
lial cells and β-tubulin III positive neuronal cells after
directed differentiation. This is the first report of a serum-
free medium that enables proliferation of USSCs and the
first to report that USSCs can be grown in suspension as
spheres, without losing their differentiation capacity.
Growing stem cells as spheres has been the initial step in
a wide range of differentiation studies, as well as studies
in pharmacogenetics, teratogenesis and tumourigenesis
[32,34-42]. Sphere formation can be facilitated by grow-
ing cells in specific medium (both serum-free and com-
plete), on non-adherent plates, in bioreactors, in agar, as
hanging drops, or by centrifugation [31,36,43]. Despite
these many studies, the significance of sphere formation is
yet to be fully understood. While it could reflect a non-
specific event, it could alternatively be an active process
essential for continued development and differentiation.
The differentiation potential of stem cells in spheres
appears to be dependent upon the starting cell population
and the medium in which the spheres are cultured. For
example, human bone marrow stromal cells can be condi-
tioned to give rise to neurospheres, which lose their stem
cell characteristics and become committed to neuronal
development [40].
To characterize the spheres derived in this study further,
we investigated a number of markers expressed in pluripo-
tent cells and in cells representative of the three germline
layers. We show that Oct4-negative USSCs give rise to
spheres, and that cells within these spheres continue to
express Sox2. Analysis of differentiation-associated mark-
ers (Nestin, Pax6, Brachyury, Goosecoid, FoxA2 and Gata6)
by RT-PCR confirms that cells cultured in USSC growth
mediumACF do not initiate a program of differentiation.
The ability of USSC spheres to maintain an undifferenti-
ated state makes them distinct from other spheres derived
from cells capable of multilineage differentiation. The
most studied of these spheres are embryoid bodies,
defined as spherical clusters of both pluripotent and com-
mitted stem cells that can organize in a developmental-
specific manner [35,42,44-48]. Unlike embryoid bodies,
USSC spheres do not commit to any differentiation pro-
grams when cultured in USSC growth mediumACF.
The cavities detected in USSC spheres are also distinct
from cavities observed in embryoid bodies. The formation
of cavities in embryoid bodies is an active process, charac-
terized by a thickening of the wall around the cavity, and
associated with the expression of endodermal-specific
markers such as Cytokeratin 8 [49,50]. While USSC
spheres can have cavities, we show that the cells surround-
Gene expression profile of three different stem cell lines  after five passages in USSC growth mediumACF Figure 6
Gene expression profile of three different stem cell 
lines after five passages in USSC growth mediumACF. 
RT-PCR for pluripotency (Sox2), ectodermal (Pax6), meso-
dermal (Gata6) and endodermal (Brachyury), associated genes 
after five passages in USSC growth mediumACF. The house 
keeping gene GAPDH was used as a positive control. Lane 1, 
hES cells; Lane 2, RT-negative control for hES cells. Lanes 3-8 
are USSCs cultured in fetal calf serum: Lane 3, USSC Line 1; 
Lane 4, RT-negative control for USSC Line 1; Lane 5, USSC 
Line 2; Lane 6, RT-negative control for USSC Line 2; Lane 7, 
USSC Line 3; and Lane 8, RT-negative control for USSC Line 
3. Lanes 9-14 are USSCs passaged five times in USSC growth 
mediumACF: Lane 9, USSC Line 1; Lane 10, RT-negative con-
trol for USSC Line 1; Lane 11, USSC Line 2; Lane 12, RT-neg-
ative control for USSC Line 2; Lane 13, USSC Line 3; and 
Lane 14, RT-negative control for USSC Line 3.BMC Biotechnology 2009, 9:101 http://www.biomedcentral.com/1472-6750/9/101
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ing the cavities and the outer layer of the sphere do not
express the endodermal marker Cytokeratin 8.
As marker analysis is insufficient to infer function, we also
analyzed the ability of the cells to respond to differentia-
tion cues. When USSC spheres are reverted to monolayer
growth and differentiated in lineage-specific medium, sur-
factant protein C-positive epithelial-like cells, β-tubulin
III-positive neuronal-like cells and Alizarin Red S-positive
bone-like cells are observed after one to five passages, con-
firming that the cells in the spheres are still multipotent.
However, derivation of spheres from a single cell and val-
idation that each cell in the sphere retains these stem cell
properties is still essential.
Conclusions
We present a new method to grow USSCs in suspension
without losing their multi-lineage differentiation capacity
in short term assays. The ability to culture these cells in a
three-dimensional spherical structure in a defined animal
component-free environment is a first step towards
improving protocols for tissue engineering, and expan-
sion of these cells in vitro.
Although there are a number of serum-free media mar-
keted for culturing other types of stem cells, USSC growth
mediumACF is unique because it enables the short term
expansion of USSCs in suspension, the formation of
spheres, and the maintenance of the multilineage differ-
entiation capacity of USSCs. Suspension culturing of cells
facilitates large scale expansion, but we note that it will
still be necessary to validate the genetic stability and safety
of cells after long term cell growth before they can be used
therapeutically. The latter is also heightened by two recent
publications using human cord to derive iPSC [51,52]
which would further expand USSC multipotentiality for
therapeutic utility, including drug discovery.
Methods
Isolation and culture of USSCs
Cord blood was collected with informed consent from
mothers undergoing elective Caesarean section. The pro-
Differentiation of spheres into neuronal, bone and epithelial-like cells Figure 7
Differentiation of spheres into neuronal, bone and epithelial-like cells. Seven days after sphere formation, cells were 
dissociated and plated on coated plates, as described in the materials and methods. The next day, cells were cultured in differ-
entiation medium. A, Neuronal differentiation was confirmed by staining with a neuronal-specific β-tubulin III antibody 
(Alexa568; red) and counter stained with 4, 6-diamidino-2-phenylindole (DAPI; blue). B, Bone differentiation cultures were 
stained with Alizarin Red S to test for mineral deposition. C, Epithelial differentiation was confirmed by RT-PCR of SPC. Lane 
1, human bronchial epithelial cell line, 16HBE14o-; Lane 2, RT-negative control of the human bronchial epithelial cell line; Lane 
3, differentiated spheres; Lane 4, RT-negative control of the differentiated spheres; Lane 5, undifferentiated spheres; Lane 6, 
RT-negative control of the undifferentiated spheres; Lane 7, USSC Line 1; Lane 8, RT-negative control of the USSC Line 1; and 
Lane 9, water control.BMC Biotechnology 2009, 9:101 http://www.biomedcentral.com/1472-6750/9/101
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Differentiation capacity of three different stem cell lines after five passages in USSC growth mediumACF Figure 8
Differentiation capacity of three different stem cell lines after five passages in USSC growth mediumACF. After 
five passages in USSC growth mediumACF, cells were dissociated and plated on coated plates, as described in Materials and 
Methods. The next day, differentiation medium was added. A, Bone differentiation cultures were stained with Alizarin Red S to 
test for mineral deposition. (i) USSC cultured in fetal calf serum; and (ii) cells cultured in USSC growth mediumACF for five pas-
sages. B, Epithelial differentiation was confirmed by RT-PCR of SPC of cells differentiated in Small Airway Growth Medium. 
Lane 1-6 USSCs passaged in fetal calf serum: Lane 1, USSC Line 1; Lane 2, RT-negative control for USSC Line 1; Lane 3, USSC 
Line 2; Lane 4, RT-negative control for USSC Line 2; Lane 5, USSC Line 3; and Lane 6, RT-negative control for USSC Line 3. 
Lanes 7-12 USSCs passaged five times in USSC growth mediumACF: Lane 7, USSC Line 1; Lane 8, RT-negative control for USSC 
Line 1; Lane 9, USSC Line 2; Lane 10, RT-negative control for USSC Line 2; Lane 11, USSC Line 3; and Lane 12, RT-negative 
control for USSC Line 3.BMC Biotechnology 2009, 9:101 http://www.biomedcentral.com/1472-6750/9/101
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tocol was approved by the University of Melbourne and
the Royal Women's Hospital Human Ethics Review Com-
mittees. After the delivery of the baby, the cord was
clamped and the blood was collected from the umbilical
cord vein in bags containing 21 ml citrate phosphate dex-
trose (Macopharma, Mouvaux, France).
The USSC lines were successfully generated as described
by Kögler et al. [1]. Briefly, the mononuclear cell fraction
was separated on a Ficoll gradient (density 1.077 g/cm3,
GE Healthcare, Uppsala, Sweden) at 400 g for 25 min fol-
lowed by lysis of erythrocytes in ammonium chloride
buffer (0.14 M ammonium chloride, 0.25 mM ethylene-
diamine-tetra-acetic acid (EDTA), 10 mM tris(hydroxyme-
thyl)aminomethane pH7.4) and two washing steps in cal-
cium- and magnesium-free phosphate-buffered saline
(PBS), pH 7.4. To initiate the growth of the adherent
USSC colonies, the mononuclear cell suspension was
plated at 2 × 106 cells/cm2 in initiation medium contain-
ing low-glucose Dulbecco's Modified Eagle's Medium
(Lonza, Walkersville, MD, USA) supplemented with 30%
fetal calf serum (Hyclone, Logan, UT, USA), 10-7 M dex-
amethasone (Sigma, St Louis, MO, USA), 100 U/ml peni-
cillin (Invitrogen, Chadsworth, CA, USA), 0.1 mg/ml
streptomycin (Invitrogen) and 2 mM Ultraglutamine
(Lonza).
Cells were incubated at 37°C in 5% CO2 in a humidified
incubator. Every five days, the non-adherent fraction was
removed and fresh medium was added. Initiation
medium was used until the first colonies appeared or for
a maximum of three weeks. Expansion of the cells was car-
ried out using initiation medium without dexamethasone
(stem cell proliferation medium). After reaching 80%
confluency, the cells were subcultured using 0.25%
trypsin/EDTA (Invitrogen), and replated at a 1:2 dilution
in stem cell proliferation medium. Low passage cells were
frozen down at 1 × 106 cells/ml in 10% dimethyl sulfoxide
(Sigma) and 50% fetal calf serum (Hyclone). For each
experiment, cells were thawed and used before they
reached passage ten.
The phenotype of the lines was as previously published
[1,8]. All the lines were negative for CD34, CD24, CD31,
CD45 and MHCII, and positive for CD44, CD71 and
MHCI. The multilineage capacity of the lines was con-
firmed by differentiation into cells representative of the
three germline layers.
Culturing in serum-free medium
Cells were cultured in three different media; PSM, HESc-
GRO™ or USSC growth mediumACF. PSM; is a basal
medium containing low-glucose Dulbecco's Modified
Eagle Medium (Cambrex BioScience), 100 U/ml penicil-
lin/0.1 mg/ml streptomycin (Invitrogen), and 2 mM Ult-
raglutamine (Cambrex BioScience) with or without 10
μM of S1P (Biomol, Exeter, UK) and 20 ng/ml PDGF
(Peprotech, NJ, USA) as described in Pebay et al., 2007.
HEScGRO™ (Millipore) was prepared according to the
manufactures instructions. USSC growth mediumACF
(Stem Cell Sciences, UK) was supplemented with 10 ng/
ml recombinant human basic fibroblast growth factor
(bFGF) (Millipore) before use.
Cells were seeded at 5.2 × 104 cells/cm2 and split 1:2 when
they reached 80% confluency. However, after one to three
passages, the cells cultured in USSC growth mediumACF
grew as non-adherent spheres without requiring any inter-
vention to initiate aggregation. To maintain sphere prolif-
eration, spheres were dissociated mechanically or using
0.25% trypsin/EDTA every four days, and allowed to
reform in USSC growth mediumACF. Cells were cultured
for five passages and then characterized further. If spheres
are not dissociated within a week they become cystic and
resistant to disaggregation by trypsinization.
Spheres were also generated using the hanging drop for-
mation [31]. Briefly, a total of 1 × 104 cells were placed in
30 μl of USSC growth mediumACF (plus or minus bFGF),
or in stem cell proliferation medium without fetal calf
serum (plus or minus bFGF), and dropped onto the inside
of a Petri dish lid. Drops were incubated upside down in
a Petri dish that contained PBS in the base to prevent
evaporation.
To confirm the cells could revert to monolayer growth,
dissociated and non-dissociated spheres were grown in
stem cell proliferation medium that contains fetal calf
serum. To determine if the cells could adhere while cul-
tured in USSC growth mediumACF, dissociated and non-
dissociated spheres were plated in Petri dishes coated with
1% gelatin (Sigma) in PBS, or 10 μg/ml fibronectin (Bec-
ton Dickinson, Franklin Lakes, NJ, USA).
Differentiation assays
Multipotency of the USSCs and the spheres was con-
firmed by differentiation into bone-, neuronal- and epi-
thelial-like cells. Spheres were dissociated with 0.25%
trypsin/EDTA (Invitrogen) and plated on 0.1% gelatin
(Sigma) in PBS-coated plates overnight before induction.
To test for mesodermal differentiation capacity of the
cells, bone differentiation assays were performed. Cells
were plated at 7 × 103 cells/cm2 cultured for ten days in
stem cell proliferation medium containing 10-7 M dexam-
ethasone (Sigma), 10 mM glycerol-6-phosphate (Sigma)
and 50 μg/ml ascorbic acid (Sigma) as described by
Jaiswal et al. [53]. Medium was replaced every five days.
To confirm successful mineralisation, cells were fixed for
ten minutes with 70% ethanol at 4°C, and stained for tenBMC Biotechnology 2009, 9:101 http://www.biomedcentral.com/1472-6750/9/101
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Neuronal differentiation capacity of three different stem cell lines after five passages in USSC growth mediumACF Figure 9
Neuronal differentiation capacity of three different stem cell lines after five passages in USSC growth mediu-
mACF. Neuronal differentiation was confirmed by staining with a neuronal-specific β-tubulin III antibody (Alexa488). A, USSCs 
cultured in fetal calf serum; and B, USSCs cultured in USSC growth mediumACF for five passages. DAPI (blue) and Alexa488 
(green) merged images shown. (Magnification ×200; scale bar is 100 μm).BMC Biotechnology 2009, 9:101 http://www.biomedcentral.com/1472-6750/9/101
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minutes with 1% Alizarin Red S (Sigma) in distilled water,
pH 4.2. The cells were then washed five times in distilled
water, layered in PBS (minus calcium and magnesium)
and phase images were captured as described below.
To demonstrate the neuronal differentiation capacity of
the cells, the differentiation protocol described by Dottori
et al. was adapted for USSCs [54]. Briefly, cells were plated
on 10 μg/ml poly-D-lysine (Sigma), 10 μg/ml fibronectin
(Becton Dickinson) coated glass coverslips and cultured
in neural basal medium consisting of Neurobasal A with
2% B-27, 1% insulin-transferrin-selenium-A, 1% N2, 2
mM L-glutamine, 100 U/ml penicillin and 0.1 mg/ml
streptomycin (all sourced from Invitrogen). Neural basal
medium was supplemented with 20 ng/ml basic fibrob-
last growth factor (R&D Systems, Minneapolis, MN, USA)
and 20 ng/ml epidermal growth factor (R&D Systems)
prior to adding to the cells. Media was changed every two
to three days, for a total culture period of 12 days at 37°C
with 5% CO2 in a humidified incubator. Differentiated
cells were fixed in 4% paraformaldehyde (BDH, Dorset,
United Kingdom) for ten minutes at 4°C and immunos-
tained overnight with 1 μg/ml of the mouse IgG1 anti-
human  β-tubulin III (Invitrogen); or 1 μg/ml mouse
IgG1negative isotype control (Dako, Glostrup, Denmark).
Cells were stained with 2 μg/ml of the goat anti-mouse
Alexa568 or 488 IgG secondary antibody (Invitrogen) and
counterstained with 0.5 μg/ml of 4, 6-diamidino-2-phe-
nylindole (DAPI, Sigma) mounted in Vectashield (Vector
Laboratories, Burlingame, CA, USA). Fluorescent images
were captured as described below.
To test for epithelial differentiation capacity of the cells,
cells were grown in Small Airway Growth Medium
(SAGM, Lonza) as described by Berger et al. [55]. Cells
were seeded at 5 × 104/cm2 in stem cell proliferation
medium the day before the addition of SAGM and then
were differentiated for eight days and medium was
changed after four days. Differentiation was assessed by
nested RT-PCR for Surfactant Protein C (SPC). RNA
extraction and PCR protocols are detailed below. The PCR
conditions for SPC were as described by Berger et al. [55],
and the human bronchial epithelial cell line, 16HBE14o-
, was used as a positive control for SPC expression [56].
Reverse transcription-polymerase chain reaction
Total RNA was isolated from 5-10 × 105 trypsinized USSCs
and from mechanically dislodged pools of spheres using
RNeasy Mini Kit (Qiagen, Germantown, MD, USA) and
RNase-Free DNase I Set (Qiagen) according to the manu-
facturer's instruction, and quantified using a NanoDrop
1000 Spectrophotometer. Reverse transcripts were pre-
Table 1: Summary of conditions and primers used for RT-PCR.
Genes Primer Sequences (5'-3') Cycles Size (bp) Annealing Temperature (°C)
Pluripotency-associated markers
Oct4 F TCTCGCCCCCTCCAGGT 30 218 53
R GCCCCACTCCAACCTGG
Sox2 F GGCAGCTACAGCATGATGCAGGACC 34 130 60
R CTGGTCATGGAGTTGTACTGCAGG
Endodermal-associated markers
FoxA2 F GGGAGCGGTGAAGATGGA 38 89 55
R TCATGTTGCTCACGGAGGAGTA
Gata6 F GAGTGAGAGAAGATGGAAGGG 38 250 55
R CGCACATGAAATCTGGATGTGG
Ectodermal-associated markers
Nestin F CAGCTGGCGCACCTCAAGATG 30 209 55
R AGGGAAGTTGGGCTCAGGACTGG
Pax6 F AACAGACACAGCCCTCACAAACA 30 275 55
R CGGGAACTTGAACTGGAACTGAC
Mesodermal-associated markers
Brachyury F GAACCAGCACCCTGTGTCCAC 38 608 57
R GCCACGACAAAAAGTCACTGC
Goosecoid F CTCAACCAGCTGCACTGTC 38 322 55
R GTCAGCTGTCCGAGTCCAAATC
Control-associated markers
GAPDH F ATGGAGAAGGCTGGGGCTC 28 196 55
R AAGTTGTCATGGATGACCTTGBMC Biotechnology 2009, 9:101 http://www.biomedcentral.com/1472-6750/9/101
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pared from 500 ng of total RNA using the SuperScript III
First-Strand Synthesis System (Invitrogen), and cDNA was
amplified using the Taq PCR Core Kit (Qiagen). Briefly,
0.4 μM of of forward and reverse primers, 0.25 U of Taq,
1× Q-solution, 1× PCR buffer containing 1.5 μM of
MgCl2, 200 μM of dNTPs and 2 μl of cDNA were used.
Table 1 contains the primer sequences, amplification con-
ditions and expected RT-PCR product sizes of all genes
investigated. The PCR conditions were as follows: 94°C
for 2 minutes; 28-38 cycles of 94°C for 30 seconds, 30 sec-
onds annealing at 51-61°C, 72°C for 1 minute; and a
final extension step at 72°C for 2 minutes.
In situ hybridization
The spheres were fixed in 4% paraformaldehyde (BDH)
for ten minutes at 4°C and incubated overnight in 20%
sucrose in PBS with calcium and magnesium (Invitrogen)
at 4°C. Cells were embedded in optimal cutting tempera-
ture compound (OCT, Tissue Tek, Japan) and stored at -
70°C. Serial sections were cut (10 μm) using a Microm
HM 550 cryostat (Carl Zeiss) and placed on Superfrost
(Menzel-Glaser, GmbH, Fisher Scientific) slides. Haema-
toxylin and eosin (Sigma) staining was performed using
standard conditions. To characterize the spheres, sections
were stained with 4.5 μg/ml mouse anti-human Cytoker-
atin 8 IgG1κ (Invitrogen) and 2.5 μg/ml of mouse anti-
human Oct4 IgG2β (Santa Cruz, CA, USA). Slides were
washed in PBS (with calcium and magnesium) with 0.1%
Tween20 (PBT), blocked for 2 hours with PBT containing
10% fetal calf serum (Invitrogen), and stained with the
primary antibody or the appropriate IgG isotype control
(Dako) overnight at 4°C. Cells were washed three times in
PBT and stained with goat anti-mouse Alexa488 second-
ary antibody (Invitrogen) for 1 hour at room temperature
and then washed three times in PBT. Before analysis,
slides were counterstained with DAPI (Sigma) 0.5 μg/ml
for five minutes at room temperature, then mounted with
Vectashield (Vector Laboratories).
Microscopy
Microscopy was performed on a fluorescent inverted
microscope (Carl Zeiss AG, Oberkochen, Germany).
Images were captured using Axiom photo system (Carl
Zeiss).
List of Abbreviations
bFGF: basic fibroblast growth factor; DAPI: 4',6-diamid-
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reverse transcription PCR; and USSC: unrestricted somatic
stem cell.
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